Advanced Systemic Mastocytosis Treatment London | KIT D816V Testing
4th June 2026
London Allergy and Immunology Centre
Advanced Systemic Mastocytosis: Diagnosis, KIT D816V Testing and New Targeted Treatments
A specialist overview for patients and clinicians on advanced systemic mastocytosis, including C findings, molecular testing, avapritinib, midostaurin and emerging KIT D816V inhibitors such as bezuclastinib.
Important: This article is for education only and does not replace specialist medical advice. Advanced systemic mastocytosis is rare and should be assessed by clinicians experienced in mast cell disorders, haematology, allergy and clinical immunology.
What is advanced systemic mastocytosis?
Systemic mastocytosis is a clonal mast cell disease in which abnormal mast cells accumulate in organs such as the bone marrow, liver, spleen, gastrointestinal tract and bones. Most patients have non-advanced disease, but a smaller group develop advanced systemic mastocytosis, where mast cell infiltration causes measurable organ damage.
Aggressive SM
Systemic mastocytosis with organ damage caused by mast cell infiltration.
SM-AHN
Systemic mastocytosis with an associated haematological neoplasm; this is the most common advanced subtype.
Mast cell leukaemia
A rare and aggressive form with a high mast cell burden and usually rapid clinical progression.
Advanced systemic mastocytosis is defined by organ damage directly caused by mast cell infiltration. These are known as C findings. Examples include low blood counts, liver dysfunction with portal hypertension or ascites, enlarged spleen with hypersplenism, malabsorption with weight loss, and significant bone disease such as large osteolytic lesions or pathological fractures.
The key diagnostic concept: C findings
Advanced systemic mastocytosis is defined by organ damage directly caused by mast cell infiltration. These are known as C findings. Examples include low blood counts, liver dysfunction with portal hypertension or ascites, enlarged spleen with hypersplenism, malabsorption with weight loss, and significant bone disease such as large osteolytic lesions or pathological fractures.
Symptoms alone are not enough
Flushing, abdominal discomfort, brain fog, bone pain, fatigue and anaphylaxis can occur in mast cell disorders, but advanced disease is diagnosed by objective organ damage, not by symptom severity alone.
KIT D816V: why molecular testing matters
Most adults with systemic mastocytosis carry the KIT D816V mutation, which drives abnormal mast cell growth and survival. Testing for KIT D816V helps confirm the diagnosis, assess disease burden and guide targeted treatment choices.
A standard next-generation sequencing panel may miss KIT D816V when the variant allele frequency is low. If clinical suspicion remains high, more sensitive techniques such as digital droplet PCR or allele-specific PCR may be needed, especially in patients with indolent or low-burden disease.
Current treatment options
| Treatment | Main role | Important safety points |
|---|---|---|
| Midostaurin | Multi-kinase inhibitor used in advanced systemic mastocytosis. | Nausea, vomiting, diarrhoea and blood count suppression may occur. |
| Avapritinib | Potent targeted KIT D816V inhibitor with deep and durable responses in advanced SM. | May cause oedema, cognitive effects and risk of intracranial bleeding. It is not recommended with very low platelet counts. |
| Cladribine | Sometimes used when rapid cytoreduction is needed. | Can suppress immunity and blood counts; requires specialist monitoring. |
| Imatinib | Only useful in selected rare cases without KIT D816V or with imatinib-sensitive mutations. | Not effective for typical KIT D816V-positive systemic mastocytosis. |
Bezuclastinib: an emerging KIT D816V inhibitor
Bezuclastinib is an investigational, next-generation KIT D816V inhibitor being studied in systemic mastocytosis. Its key mechanistic distinction is potent activity against mutant KIT D816V while aiming to spare wild-type KIT and related kinases.
Unlike avapritinib, bezuclastinib has been described in clinical development as having minimal brain penetration. This is clinically important because it may reduce concerns about cognitive adverse effects and intracranial bleeding risk. However, all targeted therapies can still have side effects and require careful specialist monitoring.
Corrected safety summary
Bezuclastinib should not be described as having a greater CNS risk than avapritinib. Current clinical development highlights its selectivity and minimal brain penetration as potential advantages. Its final place in treatment will depend on full peer-reviewed trial data, regulatory review and real-world safety experience.
Supportive care remains essential
Even when targeted treatment is used, patients with systemic mastocytosis usually need a personalised supportive care plan. This may include trigger avoidance, emergency medication, assessment of anaphylaxis risk, bone density monitoring, vitamin D optimisation, osteoporosis treatment when indicated, and review of gastrointestinal symptoms, nutrition and weight loss.
When to seek specialist review
Unexplained anaphylaxis, persistently high tryptase, abnormal blood counts, enlarged liver or spleen, unexplained weight loss, fractures, osteoporosis or suspected KIT D816V-positive disease should prompt specialist assessment.
What a specialist clinic may arrange
Assessment may include serum tryptase, blood tests, KIT D816V testing, bone density scan, allergy and anaphylaxis review, haematology input, bone marrow assessment and personalised treatment planning.
Practical action points for patients
- Ask whether your disease is non-advanced or advanced systemic mastocytosis.
- Confirm whether KIT D816V has been tested using a sufficiently sensitive method.
- Carry adrenaline auto-injectors if prescribed and ensure you know when and how to use them.
- Discuss bone density monitoring, calcium and vitamin D status, and osteoporosis prevention.
- Before avapritinib, platelet count and bleeding risk must be carefully reviewed by the treating specialist.
- Consider review in a centre with experience in mast cell disorders when the diagnosis or treatment plan is uncertain.
Specialist allergy and immunology assessment in London
London Allergy and Immunology Centre provides specialist assessment for mast cell activation symptoms, recurrent anaphylaxis, raised tryptase and suspected mast cell disorders. Patients with suspected advanced systemic mastocytosis may require coordinated care with haematology and specialist mastocytosis services.
Appointments: Please contact the clinic to arrange a specialist consultation and review of previous test results.
References and further reading
- World Health Organization and international consensus classifications of systemic mastocytosis and advanced systemic mastocytosis.
- Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders.
- DeAngelo DJ, Radia DH, George TI, et al. Avapritinib in advanced systemic mastocytosis: EXPLORER and PATHFINDER clinical trial data.
- Gotlib J, Kluin-Nelemans HC, George TI, et al. Midostaurin in advanced systemic mastocytosis.
- Cogent Biosciences. Bezuclastinib APEX study updates in advanced systemic mastocytosis.
- American Academy of Allergy, Asthma and Immunology. Mastocytosis patient information and clinical resources.
